Physician profile
Michael Kiselev
NPI 1982737003
$2,331.29
in general payments reported to CMS, 2019-2025
12 companies · $986 in 2025
The $986 reported for 2025 was more than what 94% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $65.90 · 2022: $155 · 2023: $305 · 2024: $819 · 2025: $986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,077 · Education: $32.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,077.47 |
| Education | $32.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $732.54 | 2021-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $637.16 | 2024-2025 | Tremfya |
| Abbvie INC. | $307.57 | 2021-2025 | |
| Celltrion USA INC. | $179.31 | 2024-2025 | Vegzelma, Zymfentra |
| Lilly USA, LLC | $177.66 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $81.10 | 2024 | Sucraid |
| Genzyme Corporation | $71.34 | 2024-2025 | |
| Madrigal Pharmaceuticals | $47.62 | 2024 | Resmetirom |
| Aimmune Therapeutics, INC. | $31.58 | 2025 | Vowst |
| Regeneron Healthcare Solutions, INC. | $25.03 | 2025 | Dupixent |
| Ardelyx, INC. | $23.57 | 2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $16.81 | 2023 | Linzess |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kiselev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.